ICU Medical (ICUI) KeyBanc Annual Healthcare Forum 2025 summary

2025 financial guidance and key drivers

• EBITDA guidance for 2025 is set at $395M–$425M, with adjusted EPS of $6.55–$7.25, assuming stable macro conditions and no major changes in U.S. healthcare census or currency volatility.

• Mid-single-digit growth is expected in core infusion systems and consumables, with flat performance in critical care.

• Pricing benefits from GPO contract renewals are expected to add about 1% to revenue growth, with 2025 being the last major year for such renewals.

• Gross margin improvement of about 100 basis points is expected, driven by integration synergies, price, and higher manufacturing absorption, with a target of 39–40% post-JV.

• Margin expansion targets 40% gross margin over time, with progress halfway if 2025 ends near 38%.

Tariff exposure and mitigation strategies

• Tariff exposure from Mexican manufacturing could reach $90M annually if exemptions expire, but current USMCA exemptions reduce this to under $20M.

• Additional mitigation strategies include direct exporting, 9802 provisions, and potential supply chain restructuring.

• High-effort mitigation actions are on hold pending greater clarity on long-term tariff policy.

• GPO contracts do not allow for tariff pass-through, but some flexibility exists in non-contracted business.

IV solutions market and joint venture impact

• IV solutions market has largely normalized after late 2023 disruptions.

• The joint venture with Otsuka supports growth and operational focus, aiming to combine capital and innovation, reduce capital burden, and improve competitiveness.

• JV expected to lift consolidated growth rate by about 0.5 percentage points and improve gross margins by 3–4 points post-closing.

• Additional margin benefit of 1–2 points expected after service arrangements end in several years.

• Otsuka brings a differentiated portfolio with PVC-free, DEHP-free products, multi-chamber packaging, and low-cost production.